Atlas Trials

Velicept Therapeutics, Inc.

3 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Velicept Therapeutics, Inc.

RecordFirmDate
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) (NCT03594058)Velicept Therapeutics, Inc.2018-07-09
Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women (NCT03475706)Velicept Therapeutics, Inc.2018-02-19

Track Velicept Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.